|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM350395772 |
| 003 |
DE-627 |
| 005 |
20231226044906.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202208059
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1167.xml
|
| 035 |
|
|
|a (DE-627)NLM350395772
|
| 035 |
|
|
|a (NLM)36527738
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhao, Caiyan
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a X-ray-Guided In Situ Genetic Engineering of Macrophages for Sustained Cancer Immunotherapy
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.04.2023
|
| 500 |
|
|
|a Date Revised 07.04.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Effective repolarization of macrophages has emerged as a promising approach for anticancer therapy. However, there are very few studies on the effect of reprogramming macrophages from M2 phenotype to M1 phenotype without reconversion while maintaining an activated M1 phenotype. Moreover, these immunomodulatory methods have serious drawbacks due to the activation of normal monocytic cells. Therefore, it remains a challenge to selectively reprogram tumor-associated macrophages (TAMs) without systemic toxicities. Here, X-ray-guided and triggered remote control of a CRISPR/Cas9 genome editing system (X-CC9) that exclusively activates therapeutic agents at tumor sites is established. Under X-ray irradiation, X-CC9 selectively enhances M2-to-M1 repolarization within the tumor microenvironment, and significantly improves antitumor efficacy with robust immune responses in two animal models. This strategy provides an ideal method for improving the safety of macrophage polarization and may constitute a promising immunotherapy strategy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a CRISPR-Cas9
|
| 650 |
|
4 |
|a X-rays
|
| 650 |
|
4 |
|a genetic engineering
|
| 650 |
|
4 |
|a immunomodulation
|
| 650 |
|
4 |
|a macrophages
|
| 700 |
1 |
|
|a Cheng, Yaya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huang, Pei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Changrong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Weipeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Mengjiao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shan, Wenbo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deng, Hongzhang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 14 vom: 01. Apr., Seite e2208059
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:14
|g day:01
|g month:04
|g pages:e2208059
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202208059
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 14
|b 01
|c 04
|h e2208059
|